5 terminated. 5 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Terminated 5 |
| Phase 1 | 3 | Terminated 3 |
Follow relatlimab: new trials by email Literature Review of relatlimab trials Research Report on relatlimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma Relatlimab, Nivolumab - Lymphoma, Non-Hodgkin, Hodgkin Disease | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 5 | 2022-09-13 | 2026-06-26 |
| T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer Ipilimumab, Cyclophosphamid, Fludarabine Phosphate - Metastatic Ovarian Cancer, Metastatic Fallopian Tube Cancer | Phase 1 / Phase 2 | Terminated | Inge Marie Svane | 6 | 2021-04-22 | 2025-08-12 |
| Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT Elotuzumab, pomalidomide, dexamethasone, Anti-LAG-3, Anti-LAG-3 + Pomalidimide + Dexamethasone - Multiple Myeloma, Relapsed Refractory Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Multiple Myeloma Research Consortium | 14 | 2020-07-10 | 2025-02-14 |
| Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression Nivolumab, Relatlimab, Ipilimumab - Metastatic Melanoma, Advanced Melanoma | Phase 2 | Terminated | Elizabeth Davis | 2 | 2019-01-17 | 2021-04-20 |
| An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer Nivolumab, Dasatinib, Relatlimab - Advanced Cancer | Phase 2 | Terminated | Bristol-Myers Squibb | 295 | 2016-05-09 | 2021-03-22 |
Burkitt Lymphoma (1) · Fallopian Tube Neoplasms (1) · Hodgkin Disease (1) · Lymphoma, Extranodal NK-T-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell, Peripheral (1) · Melanoma (1) · Multiple Myeloma (1) · Ovarian Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
Bristol-Myers Squibb (2) · Elizabeth Davis (1) · Inge Marie Svane (1) · Multiple Myeloma Research Consortium (1)
United States (4) · Australia (2) · France (2) · Italy (2) · Spain (2) · Austria (1) · Canada (1) · Denmark (1) · Netherlands (1) · Switzerland (1) · United Kingdom (1)
Elizabeth Davis, MD (1) · Hearn J. Cho, M.D., Ph.D. (1) · Inge Marie Svane, Prof., M.D. (1) · Madhav V. Dhodapkar, M.D. (1) · Tine J Monberg, M.D. (1)
2023 (1)